CD47/SIRPA-BLOCKING AGENT ALX148
Progesterone-Receptor Positive Breast Cancer
Explore 13 assets in Progesterone-Receptor Positive Breast Cancer →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
QuantumLeap Healthcare Collaborative
Modality
protein_peptide
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05868226CT.gov PRE-I-SPY Phase I/Ib Oncology Platform Program | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Progesterone-Receptor Positive Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| CD47/SIRPA-BLOCKING AGENT ALX148 (this asset) | QuantumLeap Healthcare Collaborative | P1 | CC · 43 |
| Tamoxifen | Jennifer Lee Caswell-Jin | P2 | BB |
| Letrozole | Ruth O'Regan | P2 | BB |
| Nivestim | University of Washington | P2 | B |
| Cyclophosphamide | University of Washington | P2 | B |
| Gefitinib | National Cancer Institute (NCI) | P2 | B |
| Palbociclib | Abramson Cancer Center at Penn Medicine | P2 | B |
| Anastrozole | Ruth O'Regan | P2 | B |
| Capecitabine | University of Washington | P2 | B |
+28 more in the Progesterone-Receptor Positive Breast Cancer cohort
Other indications for CD47/SIRPA-BLOCKING AGENT ALX148
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Cancer | — | P2 | B · 60 |
| Plasma Cell Myeloma | — | P1/2 | CCC · 48 |
| Composite Lymphoma | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. CD47/SIRPA-BLOCKING AGENT ALX148 in Progesterone-Receptor Positive Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cd47sirpa-blocking-agent-alx148-progesterone-receptor-positive-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →